Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin injection in children with spastic neurogenic bladder
IRCT20181124041743N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in neurogenic bladder and Cauda equina syndrome (CES), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Bladder capacity after injection and Hours not demanding diaper change. Started Nov 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
neurogenic bladderCauda equina syndrome (CES)
Beyond the preview
Go deeper on IRCT20181124041743N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181124041743N1.